Tradestie Institutional Equity Comparison Engine

BGMSP vs CLRB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLRB Overall Edge

CLRB Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cellectar Biosciences INC NEW (CLRB) driven by superior Growth & Margin, Momentum & Technical while BGMSP counters with relative strength in Options & Structure. Fundamentally, BGMSP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CLRB at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLRB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BGMSP N/M vs CLRB N/M Fwd P/E
Growth & Margin Winner CLRB
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner CLRB
1Y -72.6% vs -63.8% ยท 52W Pos 0% vs 0%
Options & Structure Winner BGMSP
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
1M Return -60.98%
1Y Return -72.57%
Forward P/E N/M
Unified AI Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
CLRB NASDAQ
Cellectar Biosciences INC NEW
Pharmaceutical Preparations
$1.04
-8.77% 1D
Market Cap $11.6M
1M Return -8.77%
1Y Return -63.76%
Forward P/E N/M
Unified AI Score
39.4 / 100 SELL
Tech 25.0 Fund 49.0 Flow 44.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGMSP -72.57% CLRB -63.76% Spread: +84.13 pp (CLRB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGMSP TTM Op. Margin: N/A CLRB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGMSP vs CLRB. Trailing 12-month operating profitability (BGMSP N/A vs CLRB 0.0%) and valuation multiples (BGMSP N/M vs CLRB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGMSP (1) vs CLRB (6)
Institutional Metric BGMSP CLRB Criterion Row Winner
Market Capitalization Scale N/A $11.6M Larger Scale CLRB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth CLRB
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin CLRB
Net Profit Margin Profitability N/A 0.0% Higher Margin CLRB
Return on Equity (ROE) Capital Efficiency N/A -162.6% Higher ROE CLRB
52-Week Range Position Momentum 0% ($1โ€“$14) 0% ($1โ€“$5) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 201% Vol 1.28ฮฒ ยท 81% Vol Lower Realized Risk CLRB
Unified Institutional Score Composite Signal 42.7 / 100 (HOLD) 39.4 / 100 (SELL) Higher Composite BGMSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGMSP vs CLRB Buy Guide
BGMSP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGMSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLRB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLRB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGMSP nor CLRB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.